Related Experiment Video
Updated: Sep 12, 2025

Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
Evolution of Vesicoureteral Reflux in Patients With Myelomeningocele in a Proactive Follow-Up Protocol
1Department of Urology, Hospital "Prof. Dr. Juan P. Garrahan", Pichincha 1890, C1245 CABA, Buenos Aires, Argentina.
Introduction:
In the first six months of life, patients with myelomeningocele (MMC) have an incidence of vesicoureteral reflux (VUR) between 17 and 26.3 %. A proactive treatment approach is associated with VUR resolution rates up to 30-50 % within 2-3 years. Our aim was to assess the incidence of VUR in pediatric patients with MMC and to identify the variables involved in its occurrence. We analyzed the evolution of VUR and chronic kidney disease (CKD), using a proactive approach, and compared outcomes with those of MMC patients without VUR.
Material And Methods:
This retrospective, observational study included newborns with MMC, managed proactively between 2015 and 2020 at our institution. Patients were grouped based on the presence or absence of VUR at the first videourodynamic study (VUDS). Demographic characteristics and nephron-urological variables were compared between the first and last year of follow-up.
Results:
68 patients were analyzed and 14 had VUR in the first VUDS at a mean age of 6 months (R: 2-15). Low-grade VUR was observed in 11 (78.6 %) and high-grade VUR in only three patients. The resolution rate of VUR was 64.3 % within 22 months (R: 7-49). Surgical closure of the defect beyond the first 24 hours of life was associated with VUR (p < 0.001); 57 % developed CKD.
Conclusion:
The incidence of VUR in pediatric patients with MMC was 16 %. When a proactive protocol was implemented, the resolution rate of VUR was 65 % within 2 years. Most of these patients progress to CKD.
Type Of Study:
Observational cohort study.
Level Of Evidence:
III.
Insights
The incidence of vesicoureteral reflux (VUR) in myelomeningocele (MMC) patients is 16%. A proactive approach led to a 65% VUR resolution rate within two years, though most patients still develop chronic kidney disease (CKD).
Area of Science:
- Pediatric Urology
- Nephrology
- Developmental Biology
Background:
- Myelomeningocele (MMC) is associated with a significant incidence of vesicoureteral reflux (VUR), ranging from 17% to 26.3% in the first six months of life.
- A proactive management strategy for VUR in MMC patients has shown potential for resolution rates between 30% and 50% over 2-3 years.
Purpose of the Study:
- To determine the incidence of VUR in pediatric patients with MMC.
- To identify factors associated with VUR occurrence in this population.
- To analyze the progression of VUR and chronic kidney disease (CKD) under a proactive management protocol.
Main Methods:
- Retrospective observational cohort study (Level of Evidence: III) of newborns with MMC managed proactively between 2015 and 2020.
- Patients were categorized based on the presence or absence of VUR identified via videourodynamic study (VUDS) at a mean age of 6 months.
- Demographic and nephro-urological variables were compared between initial diagnosis and the last follow-up year.
Main Results:
- The overall incidence of VUR in pediatric MMC patients was 16% (14 out of 68 analyzed).
- Low-grade VUR was predominant (78.6%), with a VUR resolution rate of 64.3% within a median of 22 months.
- Surgical closure of the MMC defect after the first 24 hours of life was significantly associated with VUR (p < 0.001); 57% of patients developed CKD.
Conclusions:
- The incidence of VUR in pediatric MMC patients is 16%, with a high resolution rate (65% within 2 years) observed under a proactive management protocol.
- Despite VUR resolution, the majority of these patients are at high risk for developing chronic kidney disease (CKD).
- Early surgical intervention timing may influence VUR development in MMC patients.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urodynamic Studies: Uroflowmetry
Imaging Studies VI: Voiding Cystourethrography and Cystography
Ureters

